Concerns Raised About India's DengiAll Vaccine Amid Vaccine Adverse Events
Key Points
Concerns have been raised about the efficacy and safety of India's DengiAll vaccine following reports of adverse events during Brazil's Butantan-DV campaign. This is significant for UPSC aspirants as it relates to GS Paper 2 (Health) and GS Paper 3 (Science & Technology). Last Updated: 16-06-2026
Key Facts About DengiAll Vaccine
- DengiAll is a live-attenuated tetravalent dengue vaccine.
- It combines four weakened dengue virus serotypes: DENV-1, 2, 3, 4.
- Concerns include antibody-dependent enhancement (ADE), which can worsen infections.
- The vaccine aims to provide immunity against all four dengue serotypes.
- Reports from Brazil's Butantan-DV campaign highlight severe adverse events.
- Monitoring and evaluation are crucial for vaccine efficacy and safety.
Global Context of Vaccine Safety
The safety and efficacy of vaccines like DengiAll are crucial for public health, impacting India's strategic goals in disease prevention and healthcare. With dengue being a significant health concern, effective vaccines can reduce disease burden and healthcare costs. Globally, vaccine safety is paramount, with international comparisons highlighting the need for robust monitoring systems.
UPSC Relevance
GS Paper 2: Health and Education - Issues relating to development and management of Social Sector/Services.
GS Paper 3: Science and Technology - Developments and their applications and effects in everyday life.
Prelims Angle: Questions on vaccine types, dengue serotypes, and ADE could be asked.
Mains Angle: Analytical themes on vaccine safety, public health policies, and international health standards.
FAQ Section
- What is the DengiAll vaccine? The DengiAll vaccine is a live-attenuated tetravalent dengue vaccine designed to provide immunity against four dengue virus serotypes.
- Why is the DengiAll vaccine important? It is crucial for controlling dengue outbreaks, which are a significant public health issue in India and other tropical regions.
- What are the key features of live-attenuated vaccines? These vaccines contain weakened pathogens that stimulate a strong immune response, providing long-lasting immunity but requiring careful handling and storage.
Detailed Coverage
- Concerns raised about India's DengiAll vaccine.
- Severe adverse events reported in Brazil's Butantan-DV campaign.
- Highlighting risks of antibody-dependent enhancement (ADE).
- Both vaccines are live-attenuated tetravalent dengue vaccines.
- Combine four weakened dengue virus serotypes (DENV-1, 2, 3, 4).
- Envelope proteins differ significantly, affecting immunity.
- Dengue vaccination produces type-specific and cross-reactive antibodies.
- Cross-reactive antibodies can enhance dengue infection if levels drop.
- Live-attenuated vaccines mimic natural infections.
- Provide strong, long-lasting immune response.
- Examples include MMR, varicella, and yellow fever vaccines.
- Advantages include strong immunity and fewer booster doses.
- Limitations: not for immunocompromised, require cold-chain storage.
- Concerns about efficacy and safety of DengiAll vaccine.
- Need for robust monitoring emphasized.
- Potential severe outcomes from ADE highlighted.